Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Argenx Se ADR
(NQ:
ARGX
)
383.34
+7.84 (+2.09%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Argenx Se ADR
< Previous
1
2
3
Next >
argenx Reports Third Quarter 2022 Financial Results and Provides Business Update
October 27, 2022
From
argenx SE
Via
GlobeNewswire
argenx to Report Third Quarter 2022 Financial Results and Business Update on October 27, 2022
October 20, 2022
From
argenx SE
Via
GlobeNewswire
argenx announces Extraordinary General Meeting of Shareholders on September 8, 2022
July 28, 2022
From
argenx SE
Via
GlobeNewswire
argenx Reports Half Year 2022 Financial Results and Provides Second Quarter Business Update
July 28, 2022
From
argenx SE
Via
GlobeNewswire
argenx to Present New Data from Generalized Myasthenia Gravis Program at 2022 American Academy of Neurology Annual Meeting
April 01, 2022
From
argenx SE
Via
Business Wire
argenx Announces Positive Topline Phase 3 Data From ADAPT-SC Study Evaluating Subcutaneous Efgartigimod for Generalized Myasthenia Gravis
March 22, 2022
From
argenx SE
Via
Business Wire
argenx Announces VYVGART™ Approval in Japan for the Treatment of Generalized Myasthenia Gravis
January 20, 2022
From
argenx
Via
Business Wire
argenx Highlights Strategic Priorities for 2022
January 07, 2022
From
argenx
Via
Business Wire
argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis
December 17, 2021
From
argenx SE
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.